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1196-13 The Impact of New Stent Implantation on Outcomes 
Fol lowing Intracoronary Brachytherapy 
Mark A. Gdse, Manuela Negoita, Roxanna Mehran, Prebhakar Tripuraneni, John P. 
Reilly, Jeffrey W. Moses, Martin S. Leon, Paul S. Teirstain, Scripps Clinic, La Jolla, 
California, Lenox Hill, New York, New York. 
Background: Late stant thrombosis has been correlated with new stant placement at the 
time of intracoronary brachytherapy. The Scripps III study tests a strategy of extended 
anti-platelet therapy and reduced stent deployment o reduce late thrombosis. The objec- 
tive of this analysis is to evaluate outcomes in patients treated with new stent placement 
at the time of intracorenary gamma radiation compared with patients who did not receive 
new stents. 
Methods: At two centers (Scdpps Clinic and Lenox Hill), vigorous attempts were made to 
avoid implanting new stants at the time of intracoronary gamma radiation. Patients who 
did not receive new stents were discharged on clopidogrel (75rng per day after a 300rag 
loading dose) for 6 months. Patients who received new stants were treated with clopi- 
dogrel for 12 months. All patients were treated with aspirin indefinitely. 
Results: Of 500 patients enrolled, 112 (22.4%) received new stents (New Stant) and 388 
(77.4%) did not (No New Stent). Mean follow up time was 337.24 days. New Stant 
patients had an increase in major adverse cardiac events (death, myocardial infarction or 
target lesion revascularization) compared to No New Stent patients (29.0% vs. 16.7%, 
p=0.007). New Stent patients had a higher incidence of myocardial infarction compared 
to No New Stent patients (12.1% vs 2.5%, p< 0.001). Three patients in New Stant group 
sustained stent thrombosis within the first 30 days versus none in the No New Stant 
group (2.8% vs 0.0%, p=0.01). No patient had stent thrombosis after 30 days in either 
group. There was a higher incidence of target lesion revascularization in New Stant 
patients (22.4% vs 13.7%, p=0.03) and a marked increase in revascularization due to 
margin restenosis (16.8% vs 9.1%, p= 0.03). 
Conclusion: Additional stent deployment at the time of intracoronary gamma radiation 
results in an increase in major adverse cardiac events. During bachytherapy procedures, 
vigorous attempts hould be make to avoid new stant placement. If new stents must be 
placed, particular care should be taken to avoid injuring lesion margins not adequately 
treated by the radiation source wire. 
1196-14 Gamma Vascular Brachytherapy Neutralizes the 
Negative Impact of Diabetes Mellitus on Clinical 
Outcomes After PCl for In-Stent Restenoeis: Pooled 
Data From Gamma I, Gamma II, and SCRIPPS III Trials 
Milena G. Adamtsn. Issam Mousse, Roxana Mehran, George Dangas, Alexandra J. 
Lansky, Gary S. Mintz, Mehran Moussavian, Andrea Abizaid, Yuliya Adamyan, Mohamed 
Mohamed, Richard Kuntz, Gregg W. Stone, Jeffrey W. Moses, Martin B. Leon, Paul S. 
"nerstein, Lenox Hill Heart and Vascular Institute, New York, New York, Cardiovascular 
Research Foundation, New York, New York. 
Background: Diabetes mellitus (DM) is a known predictor of repeat revasculadzation 
procedures following percutaneous coronary interventions (PCI). The effectiveness of 
gamma vascular brachytherapy (VBT) in reducing recurrence after treatment of in-stant 
restenosis (ISR) in diabetic patients is not well studied. 
Methods: Gamma I, II, and SCRIPPS III enrolled 750 patients to Ir-192 VBT for treat- 
ment of ISR. Pts were divided in two groups: DM (n=256), and non-DM (n= 495). 
Results: There were more female (29.8% vs.22.7%, p=0.04), and hypertensive pts 
(76.0% vs.65.4%, p=O.004) in DM compared to non-DM group. DM had higher levels of 
baseline creatinine compared to non-DM (1.35+1.7 vs. 1.11+0.7, p=0.03). New stents 
were implanted in 41.2% and 40.5% in DM and non-DM pts, respectively (p=0.9). Short 
radiation source (6 seeds) were used more often in non-DM compared to DM (9.8% vs. 
5.5%, p=0.05). Clinical FU was available in 96% of pts at 6 to 9 months. Angiographic 
data and outcomes appear in table. 
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DM (n=255) Non-DM (n=495) P-value 
Ref, Vessel Diam (mm) 3.32 + 1.8 3.28 _+ 1,5 0.7 
Lesion Length (ram) 27.1 + 16.6 27.9 ± 16.8 0.5 
FU at 6-9 months: 
Death (%) 2.8 1.5 0.3 
MI (%) 8.1 5,9 0,3 
TLR (%) 9.7 t4.6 0.07 
TVR (%) 13.8 19.4 0.06 
TLR=target lesion revascularization; TVR=target vessel revascularization 
Conclusion: Gamma radiation neutralizes the deleterious effects of DM on recurrent in- 
stent restenosis. Srechytherepy should be the first line treatment in diabetics with ISR 
lesions. 
1196-15 Does Vessel Size Have an Impact on Recurence Rates 
Following Gamma Vascular Brachytherapy: Acute and 
Nine-Month Results From SCRIPPS Ill Registry 
Milena G. Adamian, Roxana Mehran, George Dangas, Gishel New, Andrea S. Abizaid, 
Alexandra J. Lansky, Giora Weisz, Mark A. Grise, Michael B. Collins, Edward M. Kreps, 
Gregg W. Stone, Issam Mousse, Jeffrey W. Moses, Martin B. Leon, Paul S. Tairstain, 
Lenox Hill Heart and Vascular Institute, New York, New York, Cardiovascular Research 
Foundation, New York, New York. 
Background: Small reference vessel diameter (RVD) is a predictor of repeat revascular- 
ization procedures following percutaneous coronary interventions (PCI). However, it is 
unknown whether gamma vascular brechytherapy equalizes outcomes after treatment of 
in-stent restenosis (ISR) lesions in small vs larger vessels, 
Methods: SCRIPPS III was a prospective registry of ISR lesions treated with gamma 
vascular brachytharapy and prolonged (>6 months) antiplatelet herapy. SCRIPPS III 
lesions (n=500) were divided according to RVD: large (>2.75mm) vs. small (<_2.75rnm) 
vessels. 
Results: There were no differences in baseline clinical characteristics between the 
groups, except for a slightly more diabetics in the small RVD group (45% vs. 33%, 
p=0.06). Clinical FU at 9 months was available in 96% of pts. 
RVD >2,75mm RVD _< 2,75mm P-value 
(n=42S) (n=7S) 
Ref, Ves. Diam (mm) 3.44± 2.1 2.66 + 0.2 <0.0001 
Lesion Length (mm) 29.0 + 18.9 30.2 + 17.2 0.63 
New Stants (%) 14 23 0.61 
In-hosplteh 
Death (%) 0.2 0 1.00 
MACE (%) 2.6 4.6 0.41 
Late Thrombosis (%) 0 0 N/A 
9 months: 
Death (%) 1.8 1.7 1.00 
TLR (%) 15.6 16.7 0.65 
MACE (%) 19.8 20.0 1.00 
TLR=target lesion revascularization; MACE=major adverse cardiac events (death, any 
MI, subacuta stant thrombosis, TLR). 
In diabetic patients 1-year TLR was 14.4% in large RVD group vs. 18.5% in small RVD 
group (p=0.91) and MACE rates were 22.7% vs. 22.2% respectively (p=0.29). 
Conclusion: Gamma brachytherapy following PCI for in-stent restenosis equalizes in- 
hospital and long-term outcomes between the patients with both small vs large vessels. 
This important effect of brachytherapy is also present in diabetic patients. 
1196-16 Four-Year Fol low-Up After Intracoronary Gamma 
Radiation Therapy for  In-Stent Restenoais: Results 
From a Randomized Clinical Trial 
Ron Waksman, Andrew E. Ajani, R. Larry White, Edouard Cheneau, Hongsheng Wu, 
Dong-Hun Cha, Natalie Gevorkian, Veme Mattox, Regina Deible, Augusto D. Pichard, 
Lowell F. Satler, Kenneth M. Kent, Ellen Pinnow, Joseph Lindsay, Washington Hospital 
Center, Washington, DisL of Columbia. 
Background: The Washington Radiation for In-Stent Restenosis Trial (WRIST) is a dou- 
ble-blinded randomized study evaluating the effects of intracoronary radiation therapy 
(IRT) in patients (pts) with in-stant restenosis (ISR). 
Methods: One hundred and thirty pts with ISR (100 native coronary and 30 vein grafts) 
underwent PTCA, laser ablation, rotational atherectomy, and/or additional stenting (36% 
of lesions). Pts were randomized to either placebo or 1921r, with a prescribed dose of 15 
Gy to a 2 mm radial distance from the center of the source. 
Results: Angiogrephic restenosis (27% vs. 56%, p=0.002) and target vessel revascular- 
ization [TVR, (26% vs. 66%, p<0.001 )] were dramatically reduced at 6 months in IRT pts. 
Between 6 and 48 months, IRT compared to placebo pts had more target lesion revascu- 
larization (IRT=18% vs. placebo=2%, p=0.001) and TVR (IRT=19% vs. placebo=3%, 
p=0.003). At 42 months clinical follow-up, pts receiving IRT continued to have markedly 
lower MACE (TLR) rates when compared with placebo (see Figure). 
Conclusions: In WRIST, pts with in-stant restenosis treated with IRT using 1921r had a 
marked reduction in the need for repeat target lesion and vessel revascularization at 6 
months, with the clinical benefit maintained at four years. 
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